Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.

Wong JB, Bennett WG, Koff RS, Pauker SG.

JAMA. 1998 Dec 23-30;280(24):2088-93.

PMID:
9875876
2.

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.

JAMA. 2003 Jul 9;290(2):228-37.

PMID:
12851278
3.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
4.

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL.

Ann Intern Med. 1997 Nov 15;127(10):855-65.

PMID:
9382363
5.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.

Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006.

PMID:
19485429
6.

Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.

Sennfält K, Reichard O, Hultkrantz R, Wong JB, Jonsson D.

Scand J Gastroenterol. 2001 Aug;36(8):870-6.

PMID:
11495084
7.

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.

Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J.

Clin Ther. 2015 Jul 1;37(7):1529-40. doi: 10.1016/j.clinthera.2015.05.003. Epub 2015 May 29.

PMID:
26031617
8.

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators.

Health Technol Assess. 2006 Jul;10(21):1-113, iii.

9.

Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.

Kuehne FC, Bethe U, Freedberg K, Goldie SJ.

Arch Intern Med. 2002 Dec 9-23;162(22):2545-56.

PMID:
12456226
10.

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group.

Gut. 2003 Mar;52(3):425-32.

11.

Hepatitis C: an economic evaluation of extended treatment with interferon.

Shiell A, Brown S, Farrell GC.

Med J Aust. 1999 Aug 16;171(4):189-93.

PMID:
10494234
12.

The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.

Nakamura J, Kobayashi K, Toyabe S, Aoyagi Y, Akazawa K.

Eur J Gastroenterol Hepatol. 2007 Sep;19(9):733-9.

PMID:
17700257
13.

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2012 Feb 21;156(4):279-90. doi: 10.7326/0003-4819-156-4-201202210-00005.

14.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
15.

Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.

Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, Goldie SJ.

Am J Med. 2007 Mar;120(3):272-9.

16.

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW.

Clin Infect Dis. 2015 Jul 15;61(2):157-68. doi: 10.1093/cid/civ220. Epub 2015 Mar 16.

PMID:
25778747
17.

Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.

Logge C, Vettorazzi E, Fischer L, Nashan B, Sterneck M.

Transpl Int. 2013 May;26(5):527-34. doi: 10.1111/tri.12085. Epub 2013 Mar 21.

18.

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

Sagmeister M, Wong JB, Mullhaupt B, Renner EL.

Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8. Review.

PMID:
11396525
19.

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group.

J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23.

PMID:
23707373
20.

Supplemental Content

Support Center